Organogenesis Holdings Inc. (NASDAQ:ORGO) Q3 2023 Earnings Call Transcript

So that happened very quickly in HOPD and we experienced it, getting it back on formulary is a longer process through the back and other processes that they have. So we’re in that process and we’re addressing each and every one of those accounts in the office area. We’re handling those pretty much one-on-one. Fortunately, we have really strong share of voice and brand loyalty in those accounts and we’re moving them back to, Organogenesis accounts very quickly. But it’s a fourth quarter effort, as I mentioned, we are seeing a nice trend, September was the worst month, we’ve seen improvements in October, even though the month of October, we’re seeing improvements in November and that we expect to have a majority of those accounts back with us at the end of the year, which positions us really well for growth in 2024.

Ryan Zimmerman: Okay. Thanks for taking my questions.

Gary Gillheeney: Anytime.

Operator: Thank you. [Operator instructions]. We are currently showing no remaining questions in the queue at this time. That does conclude our conference for today. [Operator Closing Remarks].